Still, the best compound was progressed for a proof-of-conceptefficacy study using acute and chronic mice models of Chagas disease.Despite showing antiparasitic activity in these in vivo studies, theoptimization work with this series was stopped due to unfavorabledrug metabolism and pharmacokinetic (DMPK) properties and a deprioritizedmechanism of action (CYP51 inhibition). The gene discussed is CYP51A1; the disease is Chagas disease.